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ABSTRACT 
Malignant hyperthermia (MH) is a genetic disorder characterised by abnormal muscle 
contractures, hypermetabolism and hyperthermia. It is referred to as ' malignant' as it can 
lead to death when under anaesthetic if not recognised and treated immediately. The 
molecular basis of MH is an abnormality in the calcium release mechanism of the 
sarcoplasmic reticulum. Abnormal calcium release causes the physiological symptoms of 
an MH crisis. Genetic linkage studies have lead to the identification of the ryanodine 
receptor/Ca2+-release channel as a causative factor in MH. The ryanodine receptor is a 
large protein which is regulated by a number of ligands including ca2+, Mg2+, ATP, 
ryanodine and calmodulin. 
Most mutations in the ryanodine receptor gene that cause MH are located near two main 
regulatory regions on the receptor. Three mutations have recently been identified that are 
located in the regulatory region of the C-terrninal domain. The biochemical properties of 
one of these mutations have been studied. The current research project began to investigate 
the biochemical characteristics of the other two mutations in the C-terminal domain in 
relation to their ryanodine binding and calcium release properties. 
Sarcoplasmic reticulum vesicles were isolated from skeletal muscle samples, and an 
attempt to identify ryanodine receptors by 3H-ryanodine binding was made. RT-PCR using 
RNA extracted from a skeletal muscle sample was used to construct the cDNA for the C-
terminal transmembrane domain of the ryanodine receptor. This cDNA was cloned into a 
mammalian expression vector and introduced into COS cells. RT-PCR was also used to 
produce the cDNA encoding a small polypeptide to an antigenic region in the C-terrninal 
domain of the ryanodine receptor for the preparation of antibodies. 
Although it appeared that there may have been ryanodine receptors m the SR vesicle 
preparation as determined by immunoblotting, 3H-Ry binding to the ryanodine receptors 
was unable to confirm the presence of the receptors in the SR vesicles. Initial expression 
studies of the C-terminal domain in COS cells were inconclusive. Partial cleavage of a 
small antigenic polypeptide was obtained which could be used to produce antibodies to the 
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CHAPTER ONE - INTRODUCTION 
1.1 Malignant Hyperthermia 
1.1.1 Introduction 
Malignant Hyperthermia (MH) is a dominantly inherited, autosomal disorder of skeletal 
muscle, which is primarily triggered by exposure to volatile anaesthetic agents or 
depolarising muscle relaxants. This can lead to a sudden hyperpyrexia due to 
hypermetabolism and muscle breakdown. If not recognised and treated it progresses to a 
worsening hyperpyTexic state, muscle contractures. muscle rigidity, cardiac arrhythmias 
and other systemic effects or death (MacLennan and Phillips, 1992). 
MH is considered the most common cause of anaesthetic death in otherwise fit and healthy 
people. However, with early recognition and intervention with the correct treatment, the 
fatality rate has decreased from~ 70% to ~5% (Denborough, 1998). 
1.1. 2 Genetics of Afalignant Hyperthermia 
Extensive genetic analysis has lead to the identification of 25 point mutations in the skeletal 
muscle ryanodine receptor (RYRl) gene. In biochemical and physiological studies at least 
21 of them have been shown to have a causal role in MH (Tong et al., 1997; Jurkat-Rott et 
al., 2000; McCarthy et al., 2000). A mutation in a second gene encoding the a I-subunit of 
the dihydropyridine receptor (Monnier et al., 1997) has been shown to be responsible for 
MH in some families. These mutations account for only ~50% of MH cases (McCarthy et 
al., 2000; Richter et al., 1997). 
While the main MH locus is found on chromosome 19q13. l and encodes the RYRJ gene, 
genetic linkage studies have indicated the location of several other loci. Other genes that 
may be involved in MH susceptibility have been mapped to chromosome lq31-q32, 
3q 13.1 , 5p, 7q21-22, 7q21.1 , 17q and 17ql 1.2-q24 (reviewed in Jurkat-Rott et al., 2000; 
Loke and Maclennan, 1998; Mickelson and Louis. 1996). 
I. I . 3 Biochemist,y of Malignant Hyperthermia 
Initially, skeletal musc le was implicated in MH after observation of muscle contractures 
and an increase in serum creatine kinase levels after an MH reaction (Denborough et al., 
1970a; Denborough et al., 1970b). Creatine kinase is a protein released from muscle cells, 
which accumulates in the blood and is an indicator of the leve l of damage that has occurred 
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Figure I.I : T he molecula r effects of calcium on muscle contraction and metabolism. 
An increase in myoplasmic free calcium levels in skeletal muscle cells causes prolonged 
muscle contraction and enhanced metabolic processes. These actions lead lo the 
biochemical events that manifest as Malignant Hyperthermia (Adapted from Maclennan 
and Phillips, 1992). 
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Indeed, the main molecular defect in MI-I appears to be an abnormality in the Ca2+ -release 
mechanism in the sarcoplasmic reticulum (SR) of skeletal muscle (Mickelson et al. , 1986). 
This causes a sustained release of calcium from the SR causing an increase in the 
myoplasmic calcium concentration and it is this calcium level that regulates muscle 
contraction and metabolic activity. In normal muscle cells calcium is released from the SR 
via Ca2+- release channels and pumped back in via Ca2+-ATPases. The released calcium is 
used to initiate muscle contraction by binding to troponin in the thin filaments, and 
activating glycolysis and aerobic metabolism by binding to and activating phosphorylase 
kinase. In MI-I muscle, calcium release is increased and consequently muscle contraction 
and metabolism is enhanced which accounts for the symptoms of MH (Figure 1.1). 
The Ca2+ -release channel provides the only cellular site for the binding of the plant alkaloid 
ryanodine (Phillips et al., 1996) and hence allows for the isolation, purification and 
biochemical study of the channel (Inui et al., 1987). The properties of ryanodine binding to 
the Ca2+-release channel led to it becoming known as the ryanodine receptor (RyRl) . 
Ryanodine binding is an indirect means of measuring calcium release as it binds to the 
receptor with high affinity, in a calcium-dependent manner, when in the open state 
(Mickelson and Louis, 1996; Valdivia et al. , 1991). Specific ligands that modulate calcium 
release also affect ryanodine binding in the same way. Therefore ryanodine binding 
reflects the functional state of the channel in that channel activators or inhibitors have an 
enhancing or suppressing effect on ryanodine binding (Palnitkar et al., 1997; Richter et al. , 
1997). 
Calcium release can be modulated by a number of physiological ligands. These include 
endogenous (Ca2+, ATP, and Mg2+) and exogenous (caffeine, halothane, ryanodine, 
dantrolene, and 4-Chloro-m-cresol (4-CmC)) ligands. The Ca2+-release channel is activated 
by µM ca2+, mM ATP, nM ryanodine, caffeine, 4-CmC (a preservative added to some 
intravenous medications (Herrmann-Frank et al. , 1996)), halothane and alkaline pH. 
Inhibitors of the channel are mM ca2+, mM Mg2+, µM ryanodine, dantrolene and acidic pH 
(Loke and MacLennan, 1998; Palnitkar et al., 1997; Sarnso and Wagenknecht, 1998; 
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Valdivia et al. , 1991 ; Zorzato et al. , 1990). According to Chen et al ( 1998) Ca2+ is the 
essential regulator of the ryanodine receptor and any other modulators exert their effects by 
influencing the calcium sensitivity of the receptor. 
1.2 The Ryanodine Receptor 
The ryanodine receptor functions as the Ca2+ -release channel in the SR and is the main 
regulator of calcium concentration in skeletal muscle cells. It is composed of four identical 
subunits of ~5038 amino acids each with a molecular weight of ~565 kDa (Phillips et al., 
1996). At a total molecular weight of ~2260 kDa, the ryanodine receptor is one of the 
largest proteins and the largest ion channel known. The entire gene is ~ 160 kb long and 
contains 106 exons ranging in size from 15 base pairs to 813 base pairs (Phillips et al., 
1996). 
Three-dimensional studies show that the receptor consists of two main parts - a large 
cytoplasmic segment comprising ~80% of the structure, and a smaller (~20%) 
transmembrane domain at the C-terminal end of the protein. Hydropathy studies and 
sequence analysis have shown that the C-terminal region contains a number of 
transmembrane domains which are located in the membrane of the sarcoplasmic reticulum 
(Takeshima et al. , 1989; Zorzato et al., 1990). The cytoplasmic domain spans the gap 
between the SR and the transverse tubule (t-tubule) of the muscle cell membrane (Figure 
1.2). 
There are three known isoforms of the ryanodine receptor - RyRl, RyR2, RyR3 - which 
are encoded on separate genes and exhibit widespread expression patterns in mammalian 
tissue (Giannini et al. , 1995). RyRl is expressed mainly in skeletal muscle, but also brain 
and smooth muscle; RyR2 in cardiac muscle and also brain and endothelial cells; RyR3 in 
brain, and smooth muscle and epithelial cells (Samso and Wagenknecht, 1998). This 
widespread expression pattern may also suggest that ryanodine receptors have a role m 
calcium regulation in a rather large range of tissues (Giannini et al., 1995). 
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1.3 The Excitation-Contraction Coupling Process 
1. 3. I Excitation-Contraction Coupling 
Calcium release is caused by depolarisation of the muscle cell membrane. This signal from 
a neuronal impulse is sensed by the voltage-sensing dihydropyridine receptor (DHPR) in 
the t-tubule membrane, and passed to the ryanodine receptor in the terminal cisternae of the 
SR membrane (Figure 1.2). This occurs by a mechanism that is not fully known. 
SR 
Calsequestrin 















Figure 1.2: The excitation-contraction pathway of calcium release. 
A depolarising signal is received by the DHPR and transmitted to the ryanodine receptor 
causing a release of calcium from the sarcoplasmic reticulum. One subunit of the 
ryanodine receptor is shown along with the relative position of other proteins that are 
involved in this process and their relation to the receptor (A dapted from Pessah et al. , 
1996). 
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1.3.2 The Ryanodine Receptor and the Dihydropyridine Receptor 
The ryanodine receptor is the main component of the Ca2+ -release pathway. It is closely 
associated with the DHPR such that one DHPR associates with every alternate ryanodine 
receptor structure (Flucher and Franzini-Armstrong, 1996). 
The DHPR is a multisubunit complex with each one consisting of four domains. The al-
subunit has a cytoplasmic loop between domain II and III. This has been shown to form a 
functional interaction with the ryanodine receptor (reviewed in McPherson and Campbell, 
1993), but McPherson and Campbell ( 1993) suggested that there was no direct contact 
existing between the two proteins. Since then, it has been shown by cross-linking analysis 
that there is a direct linkage between the ryanodine receptor and the a I-subunit of the 
DHPR (Murray and Ohlendieck, 1997). Loke and MacLennan ( 1998) have identified a 
DHPR binding site near the N-terminal end of the ryanodine receptor. 
A more recent study has used NMR spectroscopy to show that the helical structural 
formation of two peptides, Al and A2, within the II - III loop of the DHPR is important for 
interaction with the ryanodine receptor (Casarotto et al. , 2000). This group suggest that 
activation of the ryanodine receptor during excitation-contraction coupling is dependent on 
the conformational changes within the II - III loop which causes the Al and A2 peptides to 
interact strongly with the ryanodine receptor. 
There also appear to be other proteins that may interact in some way with the ryanodine 
receptor and that are involved with the regulation of calcium release. These include triadin 
and calsequestrin on the luminal side, and FKBP12 and calmodulin (CaM) on the 
cytoplasmic side of the receptor. 
1.3.3 Triadin 
Initial investigators thought that triadin bound to both the ryanodine receptor and the DHPR 
(Caswell et al. , 1991 ). Later analysis indicated that only a short region of triadin was 
cytoplasmic while the majority of the protein resided in the lumen of the SR (Knudson et 
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al. , 1993). This proved that it was highly unlikely to associate with the DHPR although 
association with the ryanodine receptor was still possible. [t was also proposed that triadin 
serves as an anchor to keep calsequestrin near the ryanodine receptor in the terminal 
cistemae of the SR (reviewed in McPherson and Campbell, 1993). 
Murray and Ohlendieck ( 1997) demonstrated an association between triad in and the 
ryanodine receptor, and more recently, ryanodine binding sites have been found at various 
points on the luminal region of triad in (Caswell et al., 1999). These may bind to a position 
on the luminal loops in the C-terminal domain of the ryanodine receptor. The precise 
functional role of triadin in the excitation-contraction coupling process was not well 
defined in early 1998 (Protasi et al., 1998), although it was suggested that it may be 
involved in transmitting the Ca2+-release signal to calsequestrin (Pessah et al., 1996). 
Later in 1998, another study suggested that triadin was a negative regulator of the 
ryanodine receptor in that when triadin was present, 3H-ryanodine binding was inhibited 
and channel opening was decreased (Ohkura et al. , 1998). When triadin was removed the 
3H-ryanodine binding was increased. These authors suggested that the ryanodine receptor 
was regulated by triadin in cooperation with calsequestrin in that, while triadin inhibited the 
channel, calsequestrin was an activator of the channel. 
1. 3. 4 Calsequestrin 
Calsequestrin molecules are concentrated in the lumen of the SR. They have a high 
capacity for binding calcium, which in effect lowers the free calcium concentration within 
the SR and is one form of storage of calcium in the SR. This binding is not tight and 
signals can cause release of calcium in response to opening of the ryanodine receptor 
channel (Murray and Ohlendieck, 1997; Pessah et al., 1996; Szegedi et al., 1999). Murray 
and Ohlendieck ( 1997) showed in their linkage studies, that although calsequestrin was 
present in the terminal cisternae, it was not found in a complex of the ryanodine receptor 
and the DI-IPR. 
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Later in the same year, it was shown that calsequestrin could form a complex with the 
ryanodine receptor and also the DHPR and triadin (Zhang et al., 1997). This group found 
that junctin, another membrane protein, played a part in stabilising the complex and 
anchoring calsequestrin to the ryanodine receptor. More recently it has been found that 
when microsomal preparations are treated with halothane, a complex forms that contains 
the ryanodine receptor, DHPR as well as calsequestrin (Froemming et al., 1999). Although 
these authors suggested that calsequestrin does complex with the ryanodine receptor, it is 
still unknown whether it is a direct or indirect association. 
Szegedi et al ( 1999) have recently discovered that calsequestrin, when dephosphorylated, 
can regulate the ryanodine receptor and stimulate the subsequent release of calcium. In 
addition Herzog et al (2000) suggested that both phosphorylated and dephosphorylated 
calsequestrin could bind to the ryanodine receptor. This could prove to be a mechanism by 
which calcium is released from the SR via the alternate ryanodine receptors that are not 
associated with the voltage-sensing DHPRs. The signal or mechanism of phosphorylation 
and dephosphorylation is not known. Therefore, it remains to be seen whether it is still a 
depolarisation signal that directs the change via some other intermediate. 
1.3.5 FKBP12 
FKBP12 is a 12 kDa protein of the imrnunophilin family that binds the imrnunosuppressant 
drug FK-506 (Jayaraman et al., 1992). This protein has been identified as part of the three-
dimensional structure of the ryanodine receptor. One FKBP12 molecule has been found to 
associate with each of the cytoplasmic subunits of the ryanodine receptor and modulate its 
activity by stabilising the closed conformation of the receptor (Samso and Wagenknecht, 
1998). 
Although FKBP12 may associate tightly with the ryanodine receptor and modulate channel 
function, it can be exchanged with a soluble form or an isoforrn, or removed by drug 
treatment (Qi et al., 1998) with subsequent changes in channel function. The initial tight 
binding of FKBP 12 to the ryanodine receptor was discovered to be a weaker interaction as 
FKBP 12 could be dissociated with CHAPS detergent (Ogawa et al., 1999). Its close 
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association with the ryanodine receptor indicates that it has a role in the excitation-
contraction coupling process, which was confirmed in the study by Qi et al (1998). 
1.3.6 Calmodulin 
Calmodulin is the other protein that interacts with, and regulates the ryanodine receptor in a 
calcium dependent manner. CaM inhibits the channel in the absence of calcium or in the 
presence of higher than µM calcium. (Ogawa et al., 1999). When the channel has been 
activated by µM calcium, CaM will bind to the ryanodine receptor and inhibits the opening 
of the channel (Samso and Wagenknecht, 1998). When the intracellular concentration is in 
the nM range, more CaM binds and the receptor is activated. CaM binding sites on the 
ryanodine receptor have been identified in the central region (O'Driscoll et al., 1996) and 
also in the C-tenninal domain (Takeshima et al., 1989). 
1.4 Important Regions on the Ryanodine Receptor 
I. 4.1 Regulatory Regions 
Calcium release and ryanodine binding are modulated by various ligands - ca2+, Mg2\ 
ATP, CaM and ryanodine. Binding sites for these modulators have been predicted from 
primary sequence analysis and binding studies, and have been localised to three main 
regions on the receptor: the N-terminal domain, the centre and the C-terminal domain 
(Figure 1.3). 
The conformation of the ryanodine receptor, mediated by the N-terminal region, has been 
shown to be important for ryanodine binding. When portions of the skeletal muscle N-
terminal domain were replaced by the identical cardiac isoform segments of the ryanodine 
receptor, the high affinity binding site was lost (Nakai et al., 1999). This is because the 
skeletal muscle and cardiac muscle ryanodine receptors behave differently in their 
ryanodine binding properties. 
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Figure 1.3: A linear representation of the location of the regulatory and mutation sites 
on the ryanodine receptor. 
Regulatory regions are found over widespread areas of the receptor. The mutations are 
clustered in more compact regions. The transmembrane region of the C-terminal domain 
is almost entirely composed of regulator binding sites and contains the recently identified 
novel mutations. 
Sites on the N-terminal region include a high affinity ryanodine binding site between amino 
acid residues 500 and 1300 (Chen el al., 1993b). ATP binds between amino acids 1194 and 
1199 (Zorzato et al., 1990) and calcium binds between residues 1641 and 243 7 (Samso and 
Wagenknecht, 1998). 
The central region contains two main blocks of modulator binding sites. A low affinity 
binding site for calcium exists between amino acid residues 1872 and 1923 (Zorzato et al. , 
1990). Calmodulin binds at several sites including between residues 2807 - 2840, 2909 -
2930, 2937 - 3225 and 3614 - 3637 (O'Driscoll el al., 1996; Takeshima et al. , 1989; 
Zorzato et al. , 1990). 
The C-terminal region contains binding sites for ATP, ca2+, CaM and ryanodine. ATP 
binds at residues 4447 - 4457 (Takeshima et al., 1989; Zorzato el al., 1990). Calcium 
binds between amino acids 4253 - 4264, 4407 - 4416 and 4489 - 4499 (Chen et al., 1992; 
10 
Takeshima et al., 1989). CaM binds between residues 4295 and 4325 (Takeshima et al., 
1989). Ryanodine has a low and high affinity binding site between residue 4475 and the 
end of the C-terminal domain (Callaway et al. , 1994). 
No binding sites have been found for Mg2+ (Zorzato et al. , 1990). 
The C-terminal domain has also been found to have a major role in calcium activation and 
inactivation in skeletal muscle ryanodine receptors (Nakai et al. , 1999). When the C-
terminal domain of the skeletal muscle receptor was exchanged with the same part in the 
cardiac muscle receptor, the channel inactivation was decreased at high calcium 
concentrations. Another group has also shown that the C-terminal domain contains low 
affinity calcium binding sites (Du and MacLennan, 1999) which have an effect on 
inactivation of the channel. Cardiac muscle receptors are not inactivated by mM calcium 
like skeletal muscle receptors, but both are activated by µM calcium (Du and MacLennan, 
1999), therefore the skeletal muscle sequence can be exchanged for cardiac receptor 
sequence as was done in these two studies to examine the effects of calcium activation and 
inactivation. 
1. 4. 2 Location of Mutations associated with Malignant Hyperthermia 
The known mutations are located in clusters near or within the identified regulatory 
regions. There are two main sites: one in the N-terminal domain (residues 35 - 614) and 
one in the central portion of the receptor (residues 2163 - 2458) (Figure 1.3). 
A mutation in one of the modulator binding sequences would be expected to cause an 
alteration or reduction in the binding of that modulator leading to an alteration in the 
calcium release or ryanodine binding properties of the receptor. This occurs in malignant 
hyperthermia susceptible (MHS) muscle - calcium release and ryanodine binding is greatly 
enhanced. Seventeen mutations in the N-terminal domain and central region have been 
biochemically characterised and they have been shown to be more sensitive to caffeine and 
halothane (the in vitro diagnostic indicators) by exhibiting an increase in calcium release 
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and/or ryanodine binding (Censier et al., 1998; Richter et al., 1997; Tong et al., 1997). A 
recent study suggests that there is an interaction between the N-terminal and central 
domains, where most mutations are clustered (Yamamoto et al., 2000). In wild type 
channels an interaction occurs which closes the channel and regulates it accordingly. When 
a mutation exists, the interaction between the two domains prevents closure of the channel 
so that it remains open and increases the sensitivity of the channel to various modulators. 
This would account for the great exit of calcium ions during an MH crisis. 
Mutations which have been identified include: C35R, Rl63C, G248R, G341R, I403M, 
Y522S, R552W, R614C, R614L, R2163C, R2163H, V2168M, T2206M, T2206R, G2434R, 
R2435L, R2435H (R2436H), R2454C, R2454H, R2458C and R2458fI (Jurkat-Rott et al., 
2000; McCarthy et al., 2000). Another mutation has recently been identified, R2452W, 
which occurs in the central region of the receptor (Chamley et al., 2000) 
Two mutations have recently been identified in a different region of the receptor. They are 
located in the C-terminal domain near the third main regulatory site T4826I and H4833Y 
(Brown et al., 2000; Stowell et al., 1999). A third mutation has also been identified in this 
region, I4898T, but it is linked to another myopathy called central core disease (CDD), and 
not to MH (Lynch et al., 1999). This brings the total number of MH- or CCD-associated 
mutations to 25. 
1.5 The C-terminal Region 
1. 5.1 Models of Transmembrane Domains 
The C-terminal domain is an important region of the ryanodine receptor in that it contains a 
large regulatory region in which three MH- or CCD-associated mutations have been 
identified, two of which have not been characterised. It is also the region that contains the 
transmembrane (TM) domains. 
Sequence analysis has revealed the presence of four (Takeshima et al., 1989) or ten 
(Zorzato et al., 1990) TM domains in the C-terminal fifth of the receptor. There are still 
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discrepancies with the accuracy of the models with some groups supporting either one or 
the other. Antibodies to se lected regions were used to identify luminal sites in the C-
terminal region (Grunwald and Meissner, 1995) which supported the 4-TM model. 
Balshaw et al ( 1999) also reviewed that the 4-TM model is favo ured based on some studies 
with tryptic digestion and deletion mutations. Other research groups deduced that their 
studies of the three-dimensional structure of the receptor support the I 0-TM region model 
(reviewed in Samso and Wagenknecht, 1998). Chen et al (1993b) also support this model 
after the ir tryptic digestion studies of ryanod ine receptors in SR membrane vesicles which 
revealed that three fragments associate with the membrane. Four TM reg ions would be 
fo und in only one fragment whereas all three fragments would be needed to support the 10-
TM model. 
Other support for the 10-TM model has arisen from the study of the effects of mutations in 
a highly conserved hydrophobic region corresponding to the TM-9 domain in the Zorzato et 
al (1990) mode l (Du et al. , 1998a; Zhao et al., 1999). Bhat et al (1997) found that the 
entire C-terminal domain (~20% of the receptor) could form a fu lly functional channel, 
which would suggest that the 10-TM model is supported as all the 10 transmembrane 
domains were in the segment they studied. On the other hand, a shortened version of the 
ryanodine receptor was iso lated in brain tissue (Takeshima et al., 1993), and was highly 
homologous to the last ~2.4 kb of the C-terminal end in skeletal muscle containing the four 
transmembrane domains of the Takeshima et al ( 1989) model. However, this shortened C-
terminal region did not function as a full-length channel would. 
In the Zorzato et al ( 1990) model, the TM domains are found between amino acids 3982 -
4003, 4021 - 4040, 4277 - 430 I , 4342 - 4362, 4559 - 4581 , 4648 - 4672, 4 789 - 4821 , 
4837 - 4857, 4879 - 4899 and 4914 - 4938. The Takeshima et al (1989) model places the 
domains between residues 4564 -4581 , 4640 - 4665, 4835 - 4860 and 4917 - 4937. 
Although it is still unclear whether the 4-TM model is more accurate than the ten, both 
models support an even number of TM domains. This is consistent with the overall 
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structure of the ryanodine receptor which has an -80% cytoplasmic N-terminal portion and 
a small cytoplasmic C-tcrminal tail with the TM region in bet ween. 
l.5.2 The Calcium Channel 
initially it was assumed from sequence analysis that the T:vl segments formed the 
membrane-bound region of the calcium channel. It was also found that cDNA encoding the 
whole ryanodine receptor could be expressed in cells to form a functionally active calcium 
release channel (Chen et al., 1993a). 
Earlier in the same year, Takcshima et al ( 1993) identified a 2.4 kb mRNA species in brain 
tissue that hybridised to the C-tcrminal 656 amino acid region of the ryanodine receptor. 
The brain does express an isoform of the full-length receptor but this shortened form 
appeared to be derived from the C-terminal domain of the skeletal muscle ryanodine 
receptor using Met4382 as the initiation codon. Expression studies showed that this 
shortened form could produce a membrane protein with only four TM regions, but they 
could not obtain measurable ryanodinc binding or calcium release results comparable with 
full-length ryanodinc receptors. 
More recent studies (Bhat el al., 1997) have shmrn that the C-tcrminal domain alone is 
sufficient for channel activity. Expression of the last 1377 residues of the ryanodine 
receptor in CHO cells could produce a functionally active calcium release channel, which 
showed similar properties to the full-length version. The C-terminal domain contains 
calcium and ryanodinc binding sites (Callaway et al., l 994; Chen et al., 1992). The main 
difference with the truncated version was an inability to be inactivated by calcium, 
suggesting that the calcium binding sites in the cytoplasmic domain have a different 
function than sites in the C-te1minal domain. 
A highly conserved region identified in the C-termirnil domain of all ryanodinc receptors 
can reduce or totally abolish 3H-ryanodine binding depending on the site of the point 
mutation within the region (Zhao el al., 1999). This region relates to amino acids 4891 -
4900 in human skeletal muscle ryanodine receptor (refrr 10 appendix 5), and this group 
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suggests that it is probably the pore forming segment corresponding to the TM-9 domain in 
the Zorzato et al (1990) model. This is the location of the CCD mutation I4898T (Lynch et 
al., 1999) which abolishes ryanodine binding. 
1. 5. 3 Mutations 
Lynch et al (1999) have identified a mutation, I4898T, in the C-terminal domain of the 
ryanodine receptor in a large family that are all affected by a severe form of central core 
disease. CCD is also an autosomal, dominantly inherited disorder characterised by 
hypotonia and muscle weakness that presents early in life. It is closely associated with MH 
in that the same gene is involved and five mutations that are linked to MH are also linked to 
CCD (Tong et al., 1997). Both conditions result from an abnormality in the calcium 
release mechanism in skeletal muscle. 
The ryanodine receptor with the I4898T mutation appears to be in a closed state as 
ryanodine binding was greatly reduced. The maximum Ca2.,.. -release level was greatly 
decreased and the intracellular concentration of calcium in resting cells was significantly 
increased from normal. This suggests that the mutant channel may be 'leaky' as calcium 
stores in the SR were also greatly reduced in resting muscle cells (Lynch et al., 1999). 
The 14898T mutation appeared to behave differently to other mutations in the ryanodine 
receptor in that it reduced ryanodine binding and seemed to inactivate the channel (Balshaw 
et al., 1999). The ryanodine receptor with this mutation also had almost no response to 
caffeine or halothane, which strongly activate channel activity in MHS muscle. Zhao et al 
(1999) have also confirmed the effect of the I4898T mutation which is located in the TM-9 
highly conserved region of the ryanodine receptor. 
The Takeshima et al (1989) model places the I4898T mutation in a luminal loop of the 
receptor whereas in the Zorzato et al (1990) model it is the second to last amino acid in the 
ninth transmembrane domain heading into the luminal side (see Figure 1.4). Grunwald and 
Meissner's (1995) antibody studies also suggest that it is found in a luminal loop. The 
mutation has its greatest effect on calcium sensitivity (Lynch et al., 1999), therefore it may 
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disrupt a luminal calcium binding site, or prevent triadin binding which prevents anchoring 
of the calsequestrin/Ca2+ complexes at the terminal cisternae of the SR. 
The observation of low calcium stores in the lumen of the SR and high resting calcium 
concentration in the cytosol is consistent with this family having no MH episodes on 
exposure to anaesthetic agents (Lynch et al., 1999). This may mean that this particular 
mutation is the first to be discovered on the ryanodine receptor that is solely responsible for 
CCD and not MH. 
In light of this, and because other mutations in the N-terminal and central domains altered 
caffeine and halothane sensitivity, a study was carried out to determine the effects of the C-
terminal domain mutations on the ryanodinc receptor (Du et al., 2000). This group 
replaced amino acids 4187 4628, the most divergent region in the C-terminal domain, 
with cardiac muscle receptor sequence and observed an altered sensitivity of the channel to 
caffeine and calcium. This would suggest that mutations in this, and other regions of the C-
terminal domain could have a predictable effect on the ryanodine receptor. 
The other two mutations identified in the C-terminal domain, T4826I and H4833Y (Brown 
et al., 2000; Stowell et al., 1999), occur in families that are susceptible to MH. There is no 
evidence of CCD in either of these families. 
Biochemical analysis of these mutations has yet to be carried out to determine the effects of 
ryanodine binding and calcium release. It would be assumed that as they are both from MH 
families, as opposed to the Lynch et al ( 1999) CCD family, that both ryanodine binding and 
calcium release would be increased. 
These two mutations are located on different sides of the SR membrane depending on 
which model is employed (Figure 1 .4). The Takeshima et al (1989) model places the 
location of the mutations on the cytosolic side whereas in the Zorzato et al (1990) model 
the mutations would be on the luminal side of the SR. This is in contrast to the I4898T 
mutation. Regulation of the channel with either of these mutations would be expected to be 
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altered. But until the structure of the transmembrane domains is confirmed, the precise 
molecular effects of modulators on channel activity can not be defined. Some modulators 
may have more of an effect than others depending on which side of the SR membrane the 
mutation is on in relation to the TM model and binding site positions. Specific antibody 
binding studies could confirm the cellular location of the mutation and provide a clearer 
view as to which TM model is more accurate . 
A . • B. • • Ry R I • cy tosol 
~ - - - -r ' 
I) 
SR' ~ to- - - - to. -
o T48261 
• I 14833Y SR lumen 
o 14898T 
Figure 1.4: Schematic diagram of the location of the C-terminal domain mutations in 
relation to the transmembrane domain models. 
(A) The Takeshima et al (1989) 4-transmembrane domain model places the T48261 and the 
H4833 Y mutations on the cytosolic side of the SR membrane and the I 4898T mutation on 
the luminal side of the SR membrane. (B) The Zorzato et al (1990) 10-transmembrane 
domain model places the T48261 and the H./833 Y mutations on the luminal side of the SR 
membrane and the 14898T mutation at the second to last position on the ninth 
transmembrane domain. closest lo the luminal side of the SR membrane. 
1.6 Significance of this Project 
A total of 25 published mutations have now been identified in the ryanodine receptor of 
MHS individuals. Most of these occur within one of two groups in either the N-terminal 
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domain or the central region of the receptor. Eighteen of these mutations have been 
biochemically characterised and have been shown to be causative of the abnormal calcium 
release observed in MH muscle. Sixteen have been linked to only MH in humans, six have 
been linked to both MH and CCD (Jurkat-Rott et al., 2000; McCarthy et al., 2000; Tong et 
al., 1997) and one has been linked to CCD but not MH (Lynch et al., 1999). 
Three mutations are located in the regulatory region within the C-terminal domain. One of 
these mutations appears to be linked only to CCD and exhibits reduced calcium release and 
ryanodine binding, indicative of an inactive or closed channel. The other two mutations 
have not yet been biochemically characterised although they are associated with MH. 
1. 7 Aims of the Project 
This research project focuses on the C-terminal domain that includes a large regulatory 
region containing these novel mutations. The overall objective was to biochemically 
characterise the T4826I and H4833Y mutations in relation to their calcium release and 
ryanodine binding properties. 
Sarcoplasmic reticulum vesicles containing ryanodine receptors from normal skeletal 
muscle samples were isolated and the presence of receptors was determined by 3H-
ryanodine binding or by immunoblotting. 
The C-terminal domain of the ryanodine receptor was constructed by RT-PCR and 
expression studies were started. This would enable the introduction of point mutations into 
the C-terminal domain regulatory region so that the calcium release and ryanodine binding 
effects could be studied using recombinant protein. 
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